ARTICLE
2025 Vol 4 · No 3
EN 2ade785a669f
THE CARDIOVASCULAR BENEFITS OF ANTI-OBESITY MEDICATIONS: A GAME-CHANGER IN HEART HEALTH
Research Focus International Scientific Journal, 4(3), 149–154 · ISSN 2181-3833
Abstract
Obesity is a significant global health challenge that increases the chance of developing cardiovascular disorders (CVDs), including heart failure, coronary artery disease, and hypertension. Traditional weight-loss methods often yield limited success, prompting the need for pharmacological interventions. Anti-obesity medications (AOMs) have emerged as effective tools for not only weight reduction but also improving cardiovascular health. This article explores the cardiovascular benefits of AOMs, including their role in lowering blood pressure, improving lipid profiles, reducing inflammation, and enhancing insulin sensitivity. Clinical trials, such as the SELECT and LEADER studies, provide strong evidence that medications like semaglutide, liraglutide, and tirzepatide significantly reduce major cardiovascular events. While AOMs offer promising heart health benefits, they should be integrated into a comprehensive lifestyle approach. This review highlights the transformative impact of anti-obesity medications in reducing cardiovascular risks and improving overall well-being.
Keywords
Anti-obesity medicationscardiovascular healthobesityweight losshypertensionlipid profileinsulin sensitivityGLP-1 receptor agonistscardiovascular disease preventionmetabolic health.
How to cite
Aslam, Dr. Imran; Raza, Dr. Muhammad Kalim; Ashraf, Dr. Ayesha; Chauhan, Dr. Vishal (2025). THE CARDIOVASCULAR BENEFITS OF ANTI-OBESITY MEDICATIONS: A GAME-CHANGER IN HEART HEALTH. Research Focus International Scientific Journal, 4(3), 149–154. https://doi.org/10.66073/researchfocus.v4i3.1524